glecaprevir: Clinical Trials

37 trials of glecaprevir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

30 completed, 2 unknown, 2 withdrawn, 1 approved for marketing. 22 Phase 3, 10 Phase 2, 5 Phase 4, 3 Phase 1, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 322Completed 21, Unknown 1
Phase 210Completed 10
Phase 45Completed 2, Withdrawn 2, Recruiting 1
Phase 13Completed 3
Not applicable1Terminated 1

Follow glecaprevir: new trials by email Literature Review of glecaprevir trials Research Report on glecaprevir

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Glecaprevir/Pibrentasvir for the Treatment of PTSD
Glecaprevir / Pibrentasvir Pill - PTSD
Phase 2 / Phase 3CompletedWhite River Junction Veterans Affairs Medical Center102023-04-012024-08-29
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
Glecaprevir/Pibrentasvir (GLE/PIB) - Hepatitis C Virus (HCV)
Phase 3CompletedAbbVie2862021-08-242025-04-06
Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor
glecaprevir/pibrentasvir (GLE/PIB) - Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Phase 1 / Phase 2CompletedUniversity of California, San Diego122021-05-282022-05-24
Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs
Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet, Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet - Hepatitis C, Liver Inflammation
Not applicableTerminatedKirby Institute212021-02-122026-05-26
Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret] - End Stage Renal Disease, Chronic Hepatitis c
Phase 4WithdrawnMassachusetts General Hospital2020-11-132022-03-08
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
Sofosbuvir 400mg [Sovaldi], Glecaprevir/pibrentasvir (300mg/120mg) - Hepatitis C
Phase 4RecruitingKirby Institute302020-02-112026-07-29
Multi-center Study to Transplant Hepatitis-C Infected Kidneys
glecaprevir/pibrentasvir treatment - Renal Failure Chronic, Hepatitis C
Phase 4CompletedRaymond Chung302019-04-102022-01-26
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C
Phase 2 / Phase 3CompletedOhio State University542019-03-222023-09-13
Study of Hepatitis Eradication Receiving Protease Inhibitor Administration
glecaprevir/pibrentasivir - Coronary Artery Disease, Morality
CompletedSentara Norfolk General Hospital502019-03-202026-05-01
Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C
Direct-acting antiviral agents - Hepatitis C, Chronic
UnknownQing XIe3002019-03-062021-07-07
Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant
glecaprevir/pibrentasvir tablets - Kidney Failure, Kidney Diseases
Phase 4WithdrawnRaymond T. Chung, MD2019-02-152019-06-03
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
300mg glecaprevir/pibrentasivir 120mg - End Stage Renal Disease, Hepatitis C
Phase 4CompletedJohns Hopkins University112018-09-252021-10-19
Transplantation Using Hepatitis C Positive Donors, A Safety Trial
Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet, Ezetimibe 10Mg Oral Tablet, Ex Vivo Lung Perfusion - Lung Transplant Infection, Heart Transplant Infection
Phase 3UnknownJordan Feld402018-08-062019-07-12
A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection
Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV)
Phase 3CompletedAbbVie1002018-06-062020-03-17
A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret
Mavyret - Hepatitis C
Phase 2CompletedNYU Langone Health202018-05-122021-09-05
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
glecaprevir (300mg)/pibrentasvir (120mg) - Hepatitis C, Chronic
Phase 3CompletedKirby Institute3802017-08-212019-12-11
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV)
Phase 3CompletedAbbVie3432017-04-282020-07-13
Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet - Hepatitis C, HCV
Phase 3CompletedUniversity of Florida1772017-04-202020-02-26
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation - Hepatitis C Virus (HCV)
Phase 2 / Phase 3CompletedAbbVie1292017-03-202023-05-09
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
ABT-493 coformulated with ABT-530 - Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection
Phase 3CompletedAbbVie1532016-05-172021-07-13

Showing 20 of 37. Sign in to see all of them.

Conditions studied

Hepatitis C (33)  ·  Hepatitis C, Chronic (21)  ·  Fibrosis (4)  ·  Renal Insufficiency (4)  ·  Infections (3)  ·  Kidney Failure, Chronic (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Coronary Artery Disease (1)  ·  Hepatitis (1)  ·  Kidney Diseases (1)  ·  Renal Insufficiency, Chronic (1)  ·  Stress Disorders, Post-Traumatic (1)

Sponsors

AbbVie (22)  ·  Kirby Institute (3)  ·  Johns Hopkins University (1)  ·  Jordan Feld (1)  ·  Massachusetts General Hospital (1)  ·  NYU Langone Health (1)  ·  Ohio State University (1)  ·  Qing XIe (1)  ·  Raymond Chung (1)  ·  Raymond T. Chung, MD (1)  ·  Sentara Norfolk General Hospital (1)  ·  University of California, San Diego (1)  ·  University of Florida (1)  ·  White River Junction Veterans Affairs Medical Center (1)

Countries

United States (17)  ·  Canada (6)  ·  Australia (5)  ·  Germany (4)  ·  New Zealand (4)  ·  United Kingdom (4)  ·  France (3)  ·  Puerto Rico (3)  ·  Spain (3)  ·  Belgium (2)  ·  Italy (2)  ·  Russia (2)  ·  Austria (1)  ·  Brazil (1)  ·  Bulgaria (1)

Top investigators

David Pugatch, MD (2)  ·  Raymond T Chung, MD (2)  ·  Amin Yehya, MD (1)  ·  Armen Asatryan, MD (1)  ·  Bradley V Watts, MD, MPH (1)  ·  Christine Durand, MD (1)  ·  David R Nelson, MD (1)  ·  Gregory Dore (1)  ·  Jordan Feld, MD, MPH (1)  ·  Luis Angel, MD (1)  ·  Marianne Martinello, MD, PhD (1)

Results publications

PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 30529905, PMID 30868245, PMID 29180522, PMID 35174470, PMID 26711747, PMID 27456384, PMID 28128852, PMID 28412293, PMID 28865152, PMID 28941361, PMID 28951228, PMID 29020583, PMID 29263061, PMID 31254392, PMID 31401140, PMID 31655134, PMID 31682879, PMID 32389183, PMID 32949786, PMID 33811356, PMID 34023351, PMID 35155863, PMID 35220658, PMID 41297677, PMID 42189498, PMID 42340583

NIH funding

2015 (10), 2014 (2), 2016 (2)